Scleroderma, Diffuse: Clinical Trials

5 trials for Scleroderma, Diffuse, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 recruiting. 5 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Recruiting 5
Phase 23Recruiting 3

Follow Scleroderma, Diffuse: new trials by email Literature Review of Scleroderma, Diffuse trials Research Report on Scleroderma, Diffuse

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Belimumab - Connective Tissue Diseases
Phase 3RecruitingGlaxoSmithKline5142024-12-122026-09-09
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
CABA-201 - Systemic Sclerosis, Scleroderma
Phase 2 / Phase 3RecruitingCabaletta Bio372024-07-022026-10-16
Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate
tab baricitinib 4 mg daily, tab methotrexate 25 mg weekly with folic acid 5 mg weekly - Diffuse Cutaneous Systemic Sclerosis
Phase 3RecruitingBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh242024-01-012025-04-20
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Belimumab, Placebo - Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
Phase 2 / Phase 3RecruitingGlaxoSmithKline3002023-09-132026-09-08
Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk
clopidogrel treatment, Placebo - Scleroderma, Systemic Sclerosis
Phase 2 / Phase 3RecruitingUniversity Hospital, Bordeaux902022-06-222026-07-07

Narrower conditions

Lung Diseases, Interstitial (3)  ·  Scleroderma, Systemic (3)  ·  Autoimmune Diseases (1)  ·  Connective Tissue Diseases (1)

Broader conditions

Skin Diseases (5)  ·  Skin and Connective Tissue Diseases (5)  ·  Connective Tissue Diseases (4)  ·  Lung Diseases (3)  ·  Respiratory Tract Diseases (3)  ·  Scleroderma, Systemic (2)  ·  Immune System Diseases (1)

Interventions

belimumab (2)  ·  Folic Acid (1)  ·  Methotrexate (1)  ·  baricitinib (1)

Sponsors

GlaxoSmithKline (2)  ·  Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1)  ·  Cabaletta Bio (1)  ·  University Hospital, Bordeaux (1)

Countries

France (3)  ·  United States (3)  ·  Argentina (2)  ·  Australia (2)  ·  China (2)  ·  Greece (2)  ·  Israel (2)  ·  Japan (2)  ·  South Korea (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Bangladesh (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Denmark (1)

Top investigators

Dr MD. Fahad Hossain, MBBS, MD (1)

Results publications

PMID 41217519

NIH funding

2023 (2)